RAPT Therapeutics Inc (RAPT)
4.14
-0.10
(-2.47%)
USD |
NASDAQ |
May 16, 16:00
4.135
0.00 (0.00%)
After-Hours: 20:00
RAPT Therapeutics Research and Development Expense (Quarterly): 24.78M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 24.78M |
| December 31, 2023 | 26.76M |
| September 30, 2023 | 27.02M |
| June 30, 2023 | 21.64M |
| March 31, 2023 | 25.57M |
| December 31, 2022 | 19.45M |
| September 30, 2022 | 16.60M |
| June 30, 2022 | 14.36M |
| March 31, 2022 | 16.67M |
| December 31, 2021 | 14.30M |
| September 30, 2021 | 15.72M |
| June 30, 2021 | 13.19M |
| March 31, 2021 | 13.77M |
| Date | Value |
|---|---|
| December 31, 2020 | 10.90M |
| September 30, 2020 | 12.91M |
| June 30, 2020 | 10.99M |
| March 31, 2020 | 10.68M |
| December 31, 2019 | 10.19M |
| September 30, 2019 | 8.582M |
| June 30, 2019 | 8.267M |
| March 31, 2019 | 7.87M |
| December 31, 2018 | 8.38M |
| September 30, 2018 | 9.181M |
| June 30, 2018 | 6.90M |
| March 31, 2018 | 7.306M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.267M
Minimum
Jun 2019
27.02M
Maximum
Sep 2023
16.12M
Average
14.33M
Median
Research and Development Expense (Quarterly) Benchmarks
| Emergent BioSolutions Inc | 15.10M |
| Avinger Inc | 1.152M |
| Tonix Pharmaceuticals Holding Corp | 17.12M |
| Skye Bioscience Inc | 1.946M |
| Axsome Therapeutics Inc | 36.83M |